Federal Agencies Generally Meet Requirements for Disclosure and Review of Financial Interests Related to Lyme Disease
GAO-01-787R: Published: Jun 22, 2001. Publicly Released: Jun 22, 2001.
Additional Materials:
- Full Report:
Contact:
(202) 512-7250
contact@gao.gov
Office of Public Affairs
(202) 512-4800
youngc1@gao.gov
Some Lyme disease patients and Lyme disease organizations are concerned that federal agencies and advisors have financial interests that may affect their decisions on the funding of Lyme disease research and the approval of Lyme disease products. These agencies include the Centers for Disease Control (CDC), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA). This report reviews (1) the financial interests that CDC, NIH, and FDA employees and members of advisory committees working on Lyme disease have reported and (2) how these agencies addressed any potential conflicts of interest identified in those reports. GAO found that CDC, NIH, and FDA have generally met the requirements for disclosure and review of financial interests related to Lyme disease. Employees and special government employees (SGE's) working on Lyme disease-related activities have reported financial holdings in, and arrangements with, health sector firms, travel paid for by health sector firms, and patents related to Lyme disease. Program officials and agency officials reviewed the interests of the employees and determined that they did not present conflicts.
Mar 3, 2021
-
Drug Safety:
FDA's Future Inspection Plans Need to Address Issues Presented by COVID-19 BacklogGAO-21-409T: Published: Mar 4, 2021. Publicly Released: Mar 3, 2021.
Mar 1, 2021
-
Medicare Part B:
Payments and Use for Selected New, High-Cost DrugsGAO-21-252: Published: Mar 1, 2021. Publicly Released: Mar 1, 2021.
Feb 24, 2021
-
Covid-19:
Key Insights from GAO's Oversight of the Federal Public Health ResponseGAO-21-396T: Published: Feb 24, 2021. Publicly Released: Feb 24, 2021.
Feb 17, 2021
Feb 11, 2021
-
Operation Warp Speed:
Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing ChallengesGAO-21-319: Published: Feb 11, 2021. Publicly Released: Feb 11, 2021.
Feb 5, 2021
-
DOD Health Care:
DOD Should Monitor Implementation of Its Clinical Practice GuidelinesGAO-21-237: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
Medicaid:
CMS Needs to Implement Risk-Based Oversight of Puerto Rico's Procurement ProcessGAO-21-229: Published: Feb 5, 2021. Publicly Released: Feb 5, 2021. -
VA Health Care:
Community Living Centers Were Commonly Cited for Infection Control Deficiencies Prior to the COVID-19 PandemicGAO-21-195R: Published: Jan 6, 2021. Publicly Released: Feb 5, 2021.
Jan 28, 2021
-
COVID-19:
Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal AttentionGAO-21-265: Published: Jan 28, 2021. Publicly Released: Jan 28, 2021.
Jan 21, 2021
-
Rural Hospital Closures:
Affected Residents Had Reduced Access to Health Care ServicesGAO-21-93: Published: Dec 22, 2020. Publicly Released: Jan 21, 2021.
Looking for more? Browse all our products here